Provided by Tiger Fintech (Singapore) Pte. Ltd.

Boundless Bio, Inc.

1.09
+0.03002.83%
Volume:203.72K
Turnover:218.16K
Market Cap:24.40M
PE:-0.37
High:1.12
Open:1.04
Low:1.04
Close:1.06
Loading ...

Company Profile

Company Name:
Boundless Bio, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
64
Office Location:
10955 Alexandria Way,Suite 100,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing four products, including AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia; and AT982 for the treatment of pompe disease. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania to develop AT342, an AAV gene therapy for Crigler-Najjar Syndrome, an inherited, metabolic liver disease. The company was founded in 2012 and is based in San Francisco, California.

Directors

Name
Position
Jonathan E. Lim
Chairman and Co-Founder
Zachary D. Hornby
President, Chief Executive Officer and Director
Christine Brennan
Director
Fabio Pucci
Director
Jakob Loven
Director
Jamie Christensen
Director
Jennifer Lew
Director
Kristina Burow
Director
Nancy Whiting
Director

Shareholders

Name
Position
Zachary D. Hornby
President, Chief Executive Officer and Director
Jami Rubin
Chief Financial Officer
Chris Hassig
Chief Scientific Officer
Jessica Oien
Chief Legal Officer and Corporate Secretary
Klaus Wagner
Chief Medical Officer
Neil Abdollahian
Chief Business Officer